Active prophylaxis for respiratory syncytial virus: current knowledge and future perspectives.

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Respiratory syncytial virus (RSV) is a major cause of respiratory illness in infants, young children, and older or immunocompromised adults.
• Currently, only supportive care is available for RSV infections, with no licensed vaccine for prevention.

Purpose of the Study:

• To review the history of RSV vaccine development.
• To analyze current strategies for preventing RSV infections through vaccination.
• To discuss challenges and future directions for successful RSV vaccination.

Main Methods:

• Literature review of historical and current RSV vaccine research.
• Analysis of various vaccine platforms including live-attenuated, vector-based, subunit, nucleic acid, and particle-based vaccines.
• Discussion of obstacles such as vaccine-enhanced disease, target populations, and correlates of protection.

Main Results:

• Past vaccine development efforts, like formalin-inactivated RSV, faced issues such as vaccine-enhanced disease.
• Multiple novel vaccine approaches are under investigation, targeting different aspects of RSV immunity.
• Significant hurdles remain, including defining optimal target antigens and understanding protective immune responses.

Conclusions:

• The development of a safe and effective RSV vaccine is critical due to the virus's global health impact.
• Overcoming historical setbacks and addressing current challenges in vaccine design and evaluation is essential.
• Continued research into diverse vaccine strategies and a better understanding of protective immunity are needed for a successful RSV vaccination strategy.